Oct 25, 2024
- Corporate
Notice of Revisions to Dividend Forecast for Fiscal Year Ending December 31, 2024
Name of listed company: | Chugai Pharmaceutical Co., Ltd. |
Code number: | 4519 (Prime Market of Tokyo Stock Exchange) |
Head office: | 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo |
President & CEO: | Osamu Okuda |
Inquiries to: | Kae Miyata |
Head of Corporate Communications Dept. | |
Tel:+81-(0)3-3273-0554 |
Chugai Pharmaceutical Co., Ltd. announced that the Company resolved at the meeting of its Board of Directors held on October 25, 2024 to revise the dividend forecast per share as described below.
1. Reasons for the revision
Reflecting the significant changes in the business environment, year-end dividend forecast has been revised to Undecided. The year-end dividends will be decided after the fiscal year end based on basic profit distribution principles*. Simultaneously, the Company made a timely disclosure today through an announcement titled “Notice of Revisions to Financial Forecasts” and made upward revisions in the forecasts of revenue, core operating profit, and core earnings per share in the consolidated financial forecasts (core basis) for the fiscal year ending December 2024.
*Regarding income distribution, taking into account the strategic funding needs and earning prospects, Chugai aims for a consolidated dividend payout ratio of 45% on average in comparison with Core EPS to provide a stable allocation of profit to all shareholders.
2. Contents of the revision
Annual dividends per share | |||
---|---|---|---|
End of second quarter | End of FY | Total | |
Previous forecast | JPY 41.00 | JPY 41.00 | JPY 82.00 |
Revised forecast | Undecided | Undecided | |
Results for FY ending Dec. 2024 | JPY 41.00 | ||
Results for FY ending Dec. 2023 | JPY 40.00 | JPY 40.00 | JPY 80.00 |
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp